Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 239

1.

p28-Mediated Activation of p53 in G2-M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy.

Yamada T, Das Gupta TK, Beattie CW.

Cancer Res. 2016 Apr 15;76(8):2354-65. doi: 10.1158/0008-5472.CAN-15-2355. Epub 2016 Feb 26.

2.

p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation.

Yamada T, Das Gupta TK, Beattie CW.

Mol Pharm. 2013 Sep 3;10(9):3375-83. doi: 10.1021/mp400221r. Epub 2013 Aug 16.

PMID:
23952735
3.

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.

Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, Christov K, Ganesh L, Maker AV, Li P, Kanteti P, Das Gupta TK, Prabhakar BS.

PLoS One. 2013;8(2):e56817. doi: 10.1371/journal.pone.0056817. Epub 2013 Feb 15.

4.

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.

Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C, Rae Bressler L, Yamada T, Majumdar D, Kennedy SA, Beattie CW, Das Gupta TK.

Br J Cancer. 2013 Mar 19;108(5):1061-70. doi: 10.1038/bjc.2013.74. Epub 2013 Feb 28.

5.

A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.

Mehta RR, Yamada T, Taylor BN, Christov K, King ML, Majumdar D, Lekmine F, Tiruppathi C, Shilkaitis A, Bratescu L, Green A, Beattie CW, Das Gupta TK.

Angiogenesis. 2011 Sep;14(3):355-69. doi: 10.1007/s10456-011-9220-6. Epub 2011 Jun 11.

PMID:
21667138
6.

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.

Jia L, Gorman GS, Coward LU, Noker PE, McCormick D, Horn TL, Harder JB, Muzzio M, Prabhakar B, Ganesh B, Das Gupta TK, Beattie CW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):513-24. doi: 10.1007/s00280-010-1518-3. Epub 2010 Nov 18.

PMID:
21085965
7.

A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.

Mehta RR, Hawthorne M, Peng X, Shilkaitis A, Mehta RG, Beattie CW, Das Gupta TK.

Cancer Prev Res (Phila). 2010 Oct;3(10):1351-60. doi: 10.1158/1940-6207.CAPR-10-0024. Epub 2010 Sep 14.

8.

A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells.

Yamada T, Mehta RR, Lekmine F, Christov K, King ML, Majumdar D, Shilkaitis A, Green A, Bratescu L, Beattie CW, Das Gupta TK.

Mol Cancer Ther. 2009 Oct;8(10):2947-58. doi: 10.1158/1535-7163.MCT-09-0444. Epub 2009 Oct 6.

9.

Bacterial proteins as potential drugs in the treatment of leukemia.

Kwan JM, Fialho AM, Kundu M, Thomas J, Hong CS, Das Gupta TK, Chakrabarty AM.

Leuk Res. 2009 Oct;33(10):1392-9. doi: 10.1016/j.leukres.2009.01.024. Epub 2009 Feb 27.

PMID:
19250673
10.

Noncationic peptides obtained from azurin preferentially enter cancer cells.

Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, Green A, Bratescu L, Shilkaitis A, Beattie CW, Das Gupta TK.

Cancer Res. 2009 Jan 15;69(2):537-46. doi: 10.1158/0008-5472.CAN-08-2932.

11.

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE.

J Clin Oncol. 2007 May 20;25(15):2078-85.

PMID:
17513813
12.

Beyond host-pathogen interactions: microbial defense strategy in the host environment.

Fialho AM, Stevens FJ, Das Gupta TK, Chakrabarty AM.

Curr Opin Biotechnol. 2007 Jun;18(3):279-86. Epub 2007 Apr 23. Review.

PMID:
17451932
13.

Role of microphthalmia transcription factor (Mitf) in melanoma differentiation.

Lekmine F, Chang CK, Sethakorn N, Das Gupta TK, Salti GI.

Biochem Biophys Res Commun. 2007 Mar 16;354(3):830-5. Epub 2007 Jan 23.

PMID:
17266927
14.

Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth.

Chaudhari A, Mahfouz M, Fialho AM, Yamada T, Granja AT, Zhu Y, Hashimoto W, Schlarb-Ridley B, Cho W, Das Gupta TK, Chakrabarty AM.

Biochemistry. 2007 Feb 20;46(7):1799-810. Epub 2007 Jan 24.

PMID:
17249693
15.

Clinical trials using chemopreventive vitamin D analogs in breast cancer.

Vijayakumar S, Boerner PS, Mehta RR, Packianathan S, Mehta RG, Das Gupta TK.

Cancer J. 2006 Nov-Dec;12(6):445-50. Review.

PMID:
17207311
16.

Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy.

Mahfouz M, Hashimoto W, Das Gupta TK, Chakrabarty AM.

Plasmid. 2007 Jan;57(1):4-17. Epub 2006 Dec 12. Review.

PMID:
17166586
17.

Disrupting the entry barrier and attacking brain tumors: the role of the Neisseria H.8 epitope and the Laz protein.

Hong CS, Yamada T, Hashimoto W, Fialho AM, Das Gupta TK, Chakrabarty AM.

Cell Cycle. 2006 Aug;5(15):1633-41. Epub 2006 Aug 1.

PMID:
16861907
18.

Azurin, Plasmodium falciparum malaria and HIV/AIDS: inhibition of parasitic and viral growth by Azurin.

Chaudhari A, Fialho AM, Ratner D, Gupta P, Hong CS, Kahali S, Yamada T, Haldar K, Murphy S, Cho W, Chauhan VS, Das Gupta TK, Chakrabarty AM.

Cell Cycle. 2006 Aug;5(15):1642-8. Epub 2006 Aug 1.

PMID:
16861897
19.

Human cytochrome c enters murine J774 cells and causes G1 and G2/M cell cycle arrest and induction of apoptosis.

Hiraoka Y, Granja AT, Fialho AM, Schlarb-Ridley BG, Das Gupta TK, Chakrabarty AM, Yamada T.

Biochem Biophys Res Commun. 2005 Dec 16;338(2):1284-90. Epub 2005 Oct 24.

PMID:
16256942
20.

Resveratrol inhibits rhabdomyosarcoma cell proliferation.

Chow AW, Murillo G, Yu C, van Breemen RB, Boddie AW, Pezzuto JM, Das Gupta TK, Mehta RG.

Eur J Cancer Prev. 2005 Aug;14(4):351-6.

PMID:
16030425

Supplemental Content

Loading ...
Support Center